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http://dx.doi.org/10.1016/j.stemcr.2017.07.009SUMMARYRenal cell carcinoma (RCC) is a deadly malignancy due to its tendency to metastasize and resistance to chemotherapy. Stem-like tumor
cells often confer these aggressive behaviors. We discovered an endoglin (CD105)-expressing subpopulation in human RCC xenografts
and patient samples with a greater capability to form spheres in vitro and tumors inmice at low dilutions than parental cells. Knockdown
of CD105 by short hairpin RNA and CRISPR/cas9 reduced stemness markers and sphere-formation ability while accelerating senescence
in vitro. Importantly, downregulation of CD105 significantly decreased the tumorigenicity and gemcitabine resistance. This loss of stem-
like properties can be rescued by CDA, MYC, or NANOG, and CDA might act as a demethylase maintaining MYC and NANOG. In this
study, we showed that Endoglin (CD105) expression not only demarcates a cancer stem cell subpopulation but also confers self-renewal
ability and contributes to chemoresistance in RCC.INTRODUCTION
Renal cell carcinoma (RCC) accounts for almost 3% of all
malignancies worldwide, ranking the seventh most
common cancer in men and the ninth in women. Every
year approximately 209,000 newly diagnosed cases and
102,000 deaths can be attributed to this disease across the
world (Siegel et al., 2013). RCC is a highlymetastaticmalig-
nancy, as 30% of the patients present with metastatic
disease at diagnosis and one-third of the patients with
localized disease will relapse with distant metastasis after
nephrectomy (Hoffman and Cairns, 2011; Linehan and
Rathmell, 2012; Sudarshan et al., 2013). Several oncogenes
have been identified to be involved in the pathogenesis of
RCC, such asVHL in clear cell RCC (ccRCC) andMET in he-
reditary papillary RCC (Pantuck et al., 2010; Rini et al.,
2009). Treatments that target the downstream effectors of
these oncogenic steps, such as blocking the VEGF axis
with the antibody bevacizumab (Escudier et al., 2008) or ki-
nase inhibitor sorafenib (Larkin and Eisen, 2006), have
slightly improved progression-free survival. However, there
is a lack of treatment for relapsed ormetastatic RCC.Conse-
quently, the outcome of this group of patients is very poor,
with 5-year survival of only 11% (Larkin and Eisen, 2006).
A large volume of evidence supports the existence of can-
cer stem cells (CSCs), a rare subpopulation within solid tu-
mors that are resistant to therapy. Furthermore, their high464 Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017 j ª 2017 The Auth
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relapse after treatment (Chiou et al., 2010; Lee et al.,
2011). One of themajor challenges in the field is to identify
rare CSCs in solid tumors. Specifically, not a single univer-
sal marker is capable of identifying a CSC. It is likely that
distinctive markers are needed to isolate CSCs from
different tumor types. Bussolati et al. (2008) reported
CD105 (endoglin) as a CSC marker in human kidney can-
cer. They showed that as few as 100 CD105+ cells can
form tumors in NOD/SCID mice. However, no follow-up
study has investigated the therapeutic potential of target-
ing this CD105+ population except the differentiation ther-
apy by interleukin-15 (Azzi et al., 2011). In this study, we
further investigated the CD105+ population in human
RCC xenograft models and found that CD105 is not only
a biomarker for renal CSCs but can also serve as a func-
tional target for therapeutic intervention.RESULTS
Xenograft Tumor-Derived CD105+ Subpopulation
Displays Stem-like Characteristics with Slow
Proliferation and Increased Self-Renewal
To gain a better understanding of the contribution ofCD105
to stem-like cells in human kidney cancer, we analyzed its
expression in several kidney cancer cell lines, includingor(s).
ecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Xenograft Tumor-Derived CD105+
Subpopulation Displays Stem-like Char-
acteristics with Potential to Differentiate
(A) The relative CD105 expression profile of
different human kidney cancer cell lines
(786-O, ACHN, OS-RC-2, CAKI-1, and SN12-
PM6) is shown in western blotting (A1) and
flow cytometry (in which the positive con-
trol is human histiocytic lymphoma cell line
U-937) (A2).
(B) After cell sorting, ACHN-CD105+ cells
showed remarkably high expression (100%)
of CD105 according to both flow cytometry
(B1) and immunofluorescence staining (B2).
(C–F) qRT-PCR (C), western blotting (D), and
immunofluorescence staining (E) were
used to assess the stemness-related gene
expression in the sorted ACHN-CD105+ cells
and its parental cell line. Also, as we
cultured the sorted CD105+ cells in nutrient-
enriched differentiation medium RPMI-
1640 + 10% FBS for 2 weeks, immunofluo-
rescence (E) and qRT-PCR (F) were used to
analyze the changes in epithelial marker
CK7, mesenchymal marker VIMENTIN, and
stemness markers such as NESTIN and OCT-4
(three independent experiments were un-
dertaken for each assay. All error bars indi-
cate the mean ± SD. *p < 0.05; **p < 0.01).786-O, ACHN, OS-RC-2, CAKI-1, and SN12-PM6. Compara-
tive analysis of CD105 expression in the whole cell popula-
tion at the protein (Figure 1A1 and 1A2) level revealed the
highest level of expression in SN12-PM6 and lowest in
786-O. SN12PM6 is a highly metastatic derivative of
SN12C kidney cancer cell line developed by Fidler and co-
workers in 1989 (Naito et al., 1989). CAKI-1 is a metastatic
kidney cancer cell line derived from skin metastasis accord-
ing to the American Type Culture Collection. If CD105 de-
fines a CSC population, then only a small fraction of the
whole tumor cell population is expected to express thismarker. Indeed, the fraction of CD105+ cells ranges from
0.03% (786-0) to 0.06% (ACHN) to 2.17% (OS-RC2). The
SN12PM6 cell line and CAKI-1 are the two exception cell
lines with 93.9% and 90.93% cells expressing CD105,
respectively (Figure 1A2). Scientists have expressed concern
as to the relevance of CSCs isolated from tumor cell lines
cultured long-term in vitro compared with those from in vivo
sources. Thus, we modified our methods to analyze the
CD105+ populations from human kidney cancer xenograft
established in NOD/SCID mice (Figure S1A). We took great
caution to ensure the CD105+ cells thus harvested wereStem Cell Reports j Vol. 9 j 464–477 j August 8, 2017 465
indeed of human origin with little murine cell contamina-
tion by using PCR to assess the level of human- and
mouse-specific cytochrome C oxidase I gene (Parodi et al.,
2002) (Table S1 and Figure S1B). We analyzed the CD105+
population in xenografts derived from the canonical human
kidney cancer cell line, ACHN. As illustrated in Figure 1B1,
the CD105+ cells form a distinct population that represents
3% of the total cells within the tumor. The expression of
CD105 in each cell is remarkably robust (Figure 1B2).
A large set of stemness genes is often upregulated in CSCs
(Beier et al., 2007; Chiou et al., 2010; Kumar et al., 2012).
We verified thatNANOG,OCT-4, SOX-2, KLF-4, C-MYC (Be-
ier et al., 2007; Chiou et al., 2010; Kumar et al., 2012),
SMAD1 (Kandyba et al., 2014), SMAD2 (Sakaki-Yumoto
et al., 2013), HIF1A (Li et al., 2014), DLK-1 (Whalley,
2011), and EZH2 (Kim et al., 2015) are significantly upregu-
lated in the ACHN CD105+ compared with the parental
population by qRT-PCR (Figure 1C) and western blot (Fig-
ure 1D). The heightened expression of stemness markers
in the CD105+ populationwas further verified by immuno-
fluorescent cellular staining, and representative images of
NESTIN, OCT-4, and SOX-2 stains are shown in Figure 1E.
Likewise, these stemness genes are also upregulated in the
CD105+ population in OS-RC-2 and 786-O tumors (Fig-
ure S1D1 and S1D2). Thus far, these results demonstrate
the feasibility of isolatingCD105+ cells fromhuman kidney
cancer xenografts to study the biology of renal CSCs.
Next, we examined the stem-like properties of the
CD105+ population. We examined the differentiation po-
tential of the CD105+ cells by culturing in differentiation
medium in either RPMI-1640 plus 10% fetal bovine serum
(FBS) or DMEM high-glucose (DMEM-HG) plus 10% FBS.
The starting CD105+ population appeared to be mesen-
chymal-like with high expression of VIMENTIN and low
expression of cytokeratin 7 (CK7) (Figure 1E, left panel). Af-
ter culturing for 2 weeks in RPMI-1640 with 10% FBS, the
population converted to epithelial-like cells with increased
expression of CK7 and decreased VIMENTIN (Figure 1E).
The cellular differentiation occurred concurrently with
the downregulation of a set of stemness-related genes
including CXCR4, OCT-4, NANOG, DLK-1, and EZH2 (Fig-
ure 1F). Similar results were also observed with DMEM-
HG with 10% FBS (Figure S1C). We next analyzed the
growth characteristics of this CSC population. Cell-cycle
analysis showed that a much higher proportion (13.48%
± 2.74%) of CD105+ were arrested in G0 stage than in the
parental population (2.84% ± 0.59%) (Figure 2A), which
is also seen in hepatocellular CSCs (Kamohara et al.,
2008). Consistent with the idea that the CSC population
is a dormant one, we also found that CD105+ cells prolifer-
atedmore slowly than the parental population asmeasured
by the colorimetric cell-counting CCK8 assay (Figure 2B),
5-ethynyl-20-deoxyuridine (EdU) assay to measure DNA466 Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017synthesis (Figure 2C), and colony-formation assay (Fig-
ure 2D). Furthermore, the proportion of cell population
undergoing senescence, identified by a positive b-galactosi-
dase staining, was much higher in parental population
than in CD105+ cells, which indicated that the CD105+
population is ‘‘younger’’ (Figure 2E). In the sphere-forma-
tion assay, the CD105+ cells produced 3-fold more spheres
than the parental population, indicating its higher self-
renewal potential (Figure 2F).
CD105 Demarcates a Chemotherapy-Resistant
Population
CSCs are thought to be the subpopulation that can with-
stand and survive therapeutic insults, eventually leading
to disease relapse and progression. To investigate chemo-
therapy resistance in our model, we analyzed the response
of CD105+ and parental populations to two common
chemotherapeutic agents, cisplatin and gemcitabine. As
shown in Figure 3A, CD105+ cells were found to be more
resistant to cisplatin with a maximum inhibitory concen-
tration (IC50) of 107.15 ± 1.33 mM compared with an IC50
of 49.96 ± 1.05 mM for the parental population after 72 hr
of treatment in vitro. The differential treatment response
to gemcitabine showed a similar difference, with the esti-
mated IC50 of 66.01 mM and 34.85 mM for the CD105
+
and parental populations, respectively (Figure 3B).
Next, we profiled the expression of several genes known
to contribute to drug resistance in our models. As shown in
Figure 3C, cytidine deaminase (CDA), activation-induced
CDA (AICDA), and ATP-binding cassette (ABC) transporters
such as ABCB1, ABCC1, ABCC2, and ATM are all upregu-
lated in the CD105+ population. CDA is dramatically upre-
gulated by more than 1,000-fold, while AICDA is increased
by more than 30-fold in the CD105+ population (Fig-
ure 3C). CDA and AICDA are two important genes known
to regulate resistance to gemcitabine by deaminating gem-
citabine to 20,20-difluorodeoxyuridine.
ABC transporters are a class of membrane proteins that
mediate chemoresistance by actively pumping chemother-
apeutic agents out of the cells. In our analysis, ABCC1,
ABCC2, ABCB1, and ATMs were found to be increased to
different extents in the sorted CD105+ population. Also,
SIRT1 (Chen et al., 2014), SMAD1/SMAD2 (Paldino et al.,
2014), BCL2 (Ma et al., 2008), and ATR (Abdullah and
Chow, 2013; Maugeri-Sacca` et al., 2012), together with
ALDH1A3 (Canino et al., 2015) and MGMT (Beier et al.,
2011), were all found to be upregulated (data not shown),
which have also been reported in other CSCs or stem cells.
CD105+ Cells Are More Tumorigenic than Parental
Cells
Serial transplantation assay is one of the essential experi-
ments to examine the tumor-initiating capabilities of
Figure 2. Xenograft Tumor-Derived CD105+ Cells Are Less Proliferative with Increased Self-Renewal
(A) Cell-cycle analysis showed that a much higher proportion of CD105+ cells were arrested in the G0 stage (13.48% ± 2.74%) compared
with the parental population (2.84% ± 0.59%).
(B–F) Colorimetric cell count CCK8 assay (B), EdU assay (C), and colony-formation assay (D) showed that CD105+ cells proliferate more
slowly than parental cells. However, the colony-formation assay (D), b-galactosidase assay (E), and sphere-formation assay (F) proved that
CD105+ subpopulation has an enhanced self-renewal capability is younger compared with parental cells.
Three independent experiments were undertaken for each assay. All error bars indicate the mean ± SD. *p < 0.05; **p < 0.01.CSCs. As shown in Figure 4A, 13 102, 13 104, and 13 106
cells of CD105+ and its parental cell line were injected into
the subcapsular space of kidney in NOD/SCID mice. TheCD105+ group can produce tumors with as few as 1 3 102
cells. The heightened tumorigenicity of the CD105+
population compared with the parental cell group wasStem Cell Reports j Vol. 9 j 464–477 j August 8, 2017 467
Figure 3. The CD105+ Renal Cancer Subpopulation Is Resistant to Cisplatin and Gemcitabine with Elevated Chemoresistance
Molecular Profile
(A and B) Chemoresistance assays with two classical chemotherapy agents for cancers: cisplatin (A) and gemcitabine (B).
(C) Chemoresistance-related gene profile analysis via qRT-PCR.
Three independent experiments were undertaken for each assay. All error bars indicate the mean ± SD. **p < 0.01.demonstrated by the incidence and weight of tumor (Fig-
ures 4A and 4C). Additionally, labeling of cells with EGFP
permitted in vivo fluorescence imaging (Figure 4B). To
examine the tissue architecture of our tumor xenografts
in finer detail, we employed immunohistochemical stain-
ing with human-specific MHC-I, which revealed a clear
demarcation of the cancerous tissue from the adjacent
normal renal glomeruli and distal tubules (Figure 4D).
Knockdown of CD105 Diminishes Self-Renewal
Potential, which Can Be Rescued by CDA,MYC, or
NANOG
To investigate the functionality of CD105, we employed
short hairpin RNA (shRNA)-mediated knockdown technol-
ogy and confirmed its effectiveness in downregulating
CD105 expression by qRT-PCR (Figure 5A1) and western
blotting (Figure 5A2). Interestingly, stemness genes
CXCR-4, NANOG, DLK1, SOX-2, OCT-4, KLF4, and C-MYC
were decreased concomitantly upon silencing of CD105
(Figure 5A3). CD105 knockdown also disables the self-
renewal capability of CD105+ cells as assessed by the468 Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017sphere-formation assay, shown in Figure 5B1 and 5B2.
Next we assessed whether forced re-expression of some of
the downregulated genes after CD105 knockdown could
restore self-renewal potential. Remarkably, overexpression
of CDA, MYC, or NANOG individually in the CD105-
silenced CD105+ cells (CD105+-shENG) was able to restore
the sphere-forming capability (Figure 5C1 and 5C2), with
concomitant upregulation of the stemness genes CD105
(ENG), CDA, MYC, NANOG, MEST, AICDA, CXCR4, and
DLK-1, but not OCT-4, as shown in Figures 5D–5F. The
mechanism regulating the expression of these stemness
genes are unknown at this time.
Knockdown of CD105 Debilitates Tumorigenicity,
Accelerates Cell Senescence, and Abrogates
Chemoresistance
Next we assessed the contribution of CD105 to tumor
formation in vivo. As shown in Figure 6A1–6A3, renal tu-
mor formation can be established by implanting as few
as 1 3 102 CD105+ cells. However, a much higher cell
dosage was required to establish tumors with the CD105
Figure 4. The CD105+ Renal Cancer Subpopulation Is More Tumorigenic than CD105 Parental Cells In Vivo
(A and B) The in vivo orthotopic xenograft model shows that sorted CD105+ cells are more capable of forming tumors in the kidney than its
parental cells both in the gross view (A, arrowheads indicate the kidney with tumor) and in the in vivo imaging by GFP (B, circles pointed
out by arrowheads indicate where kidney tumor developed).
(C) The tumor weight and the incidence of tumorigenesis between the two groups in (A) and (B).
(D) Representative figure showing the typical orthotopic kidney cancer in NOD/SCID mice and immunohistochemical staining with human-
specific MHC-I antibody differentiating the tumor tissue and normal tissue.
Fifteen mice were used for each group and five for each cell dilution in each group, but only three in each cell dilution of each group are
shown as representative. There were 30 mice in total for these two groups. All error bars indicate the mean ± SD. *p < 0.05.knockdown cells (1 3 106/mouse). An increase in cell
senescence brought on by CD105 silencing likely contrib-
uted to the reduced tumor-formation ability of these
CD105+-shENG cells (Figures 6B and S4A).
CSCs are postulated to play an integral role in chemo-
therapy resistance. Thus, we compared the impact of
CD105 knockdown on gemcitabine sensitivity in CD105+
cells. As shown in Figure 7A, silencing CD105 increased
the sensitivity of these cells to gemcitabine, which was
correlated with the downregulation of a set of chemoresist-
ance genes (ABCB1, ABCC1, ABCC2, and ATM) together
with deaminases (CDA and AICDA) (Figure 7B). Similar
to the results observed for self-renewal and tumorigenicity,
the forced overexpression of CDA, MYC, or NANOG in the
CD105+-shENG cells restored chemoresistance (Figures
7C–7E). To verify the chemoresistance of CD105+ cells
in vivo, ACHN tumors were established and treated with
gemcitabine via intraperitoneal injection. The proportion
of CD105+ cells was found to be remarkably increased after
gemcitabine treatment (Figure 7F), indicating that CD105+stem-like cells are the chemoresistant cell population
in vivo. This finding has been corroborated by studies in
lung cancer, ovarian cancer, colorectal cancer, and breast
cancer.DISCUSSION
The concept of ‘‘renal CSC’’ was investigated by Camussi
and coworkers in 2003, when they isolated renal CSCs by
fluorescence-activated cell sorting from ccRCC patients’ tu-
mor samples. Subsequently, Qiu and colleagues identified a
cancer stem-like cell side population in the cell line 769P
(Huang et al., 2013), and Zhong et al. (2010) adopted the
sphere-formation assay to enrich CSCs within the human
cancer cell line SK-RC-42. Similar CSC subpopulations
have been widely reported in cell lines from other cancers,
such as glioblastoma, prostate cancer, and gastric cancer.
However, it remains controversial whether the cancer
stem-like cells isolated from cell lines are equivalent toStem Cell Reports j Vol. 9 j 464–477 j August 8, 2017 469
Figure 5. Knockdown of CD105 in the
CD105+ Renal Cancer Subpopulation
Greatly Diminishes the Expression of
Stemness Genes and Sphere-Formation
Ability of CDA, MYC, and NANOG
(A)The knockdown of CD105 in ACHN-
CD105+ cell line was verified by qRT-PCR
(A1) and western blotting (A2). Accompa-
nied by CD105 downregulation, a series of
stemness-related genes were found to be
downregulated (A3), including NANOG,
C-MYC, and CDA (see Figure 7B).
(B–F) Simultaneously, sphere-formation
ability was also diminished after knockdown
of CD105 in ACHN-CD105+ cells (B1 and B2).
After overexpressing NANOG, C-MYC, and
CDA independently, the sphere-formation
ability was rescued (C1 and C2) and the
possible downstream gene expression pro-
file were examined by qRT-PCR (D–F).
Three independent experiments were under-
taken for each assay. *p < 0.05; **p < 0.01.those isolated from in vivo sources. Many investigators
incorporated additional functional phenotype-based
methods such as sphere-formation assay, Hoechst dye-
exclusion method, or aldehyde dehydrogenase (ALDH) ac-
tivity assay to define the CSC population with more cer-
tainty. Although Khan et al. (2016) sorted CD105+ popula-
tions from kidney cancer cell lines such as ACHN and
CAKi-2, they failed to verify the CSC behavior of the sorted
cell population in vivo and neglected the involvement of470 Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017the tumor microenvironment in CSC development and
maintenance (Borovski et al., 2011). Therefore, in this
study we investigated the use of endoglin (CD105) to
isolate putative renal CSCs from xenograft tumors derived
from human kidney cancer cell lines rather than the cell
lines, and exploredCD105 function in renal CSCs. Interest-
ingly, no statistical difference was found between the
ACHN xenograft parental cells and the CD105+ cells sorted
directly from ACHN cell line in the sphere-formation assay
Figure 6. Knockdown of CD105 in CD105+ Cells Debilitates the Tumorigenic Ability In Vivo and Accelerates Tumor Cell Senescence
(A) After knockdown of CD105 in ACHN-CD105+ cells, in vivo orthotopic xenograft assay showed that the tumorigenicity of ACHN-CD105+
cells was greatly diminished after CD105+ knockdown both grossly (A1) and using in vivo imaging of EGFP (A2). Tumor incidence for each
group as well as the tumor weight is shown in (A3).
(B) Cell senescence as measured by b-galactosidase, showing elevated senescence in the CD105 knockdown cells.
For the animal study, 15 mice were used for each group and five for each cell dilution in each group, but only three mice in each cell dilution
of each group are shown as representative. There were 30 mice in total for these two groups. Three independent experiments were un-
dertaken for cell senescence assay. *p < 0.05; **p < 0.01.(Figure S2), indicating the difference of CD105+ subpopula-
tion from the cell line and the in vivo xenograft in their self-
renewal potential, as well as the potential involvement of
the tumormicroenvironment. This modifiedmethodology
enabled us to identify a rare, but distinct, CD105-express-
ing population from several human kidney cancer xeno-
grafts that possess a prominent stemness gene signature,
expressing high levels of NANOG, C-MYC, KLF-4, OCT-4,
and C-MYC.
To functionally characterize the stemness of the CD105+
population, we focused on xenografted ACHN tumors. The
CD105+ cells retain differentiation potential, and exhibit
enhanced self-renewal, less senescence, and greater tumor-
igenicity compared with the parental population. Further-
more, the CSC population showed greatly increased
expression of CDA, contributing to its chemoresistant
phenotype. The CD105+ cells are more quiescent with a
higher proportion in the G0 stage, a characteristic mani-
fested in other CSC populations, such as the extreme case
of melanoma JARID1B+ cells, whose doubling time is over
4 weeks (Roesch et al., 2010). Interestingly, HIF1A is one
of the critical factors involved in kidney cancer develop-
ment and is known to suppress tumor cell growth (Shen
et al., 2011). The upregulation of HIF1A in CD105+ cellscould in part contribute to the slow proliferation pheno-
type of this population (Schokrpur et al., 2016).
Endoglin (ENG, CD105) is a homodimer coreceptor in
the transforming growth factor b (TGFb) signaling pathway
and primarily interacts with TGFbR-I and TGFbR-II, which
serve as receptors primarily for TGFbI and TGFbIII, and to a
lesser extent TGFbII (Guerrero-Esteo et al., 2002; Koleva
et al., 2006). It is highly expressed in proliferating endothe-
lial cells and immune cells. CD105 has been found to play a
critical role in angiogenesis, as congenital mutation of
CD105 leads to hereditary hemorrhagic telangiectasia
type I, a syndrome of arteriovenous malformation and tel-
angiectasia. Hence, earlier studies widely reported its utility
as a diagnosticmarker for angiogenesis in numerous cancer
types, including renal cancer (Saroufim et al., 2014). Many
recent studies suggest that CD105 has a tumor-intrinsic
role in oncogenesis. Several studies indicate that CD105
plays a tumor-suppressive role in esophageal squamous
cell carcinoma and prostate cancer (Henry et al., 2011;
Wong et al., 2008). However, the preponderance of evi-
dence suggests that CD105 promotes metastasis and che-
moresistance (Dales et al., 2003; Pal et al., 2014). The
opposing functional activity of CD105 might be attributed
to its different isoforms. To date, three isoforms of CD105Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017 471
Figure 7. Knockdown of CD105 in CD105+
Cells Abrogates Gemcitabine Resistance,
and This Effect Can Be Reversed by Subse-
quent Overexpression of CDA, MYC, or
NANOG
(A and B) Knockdown of CD105 in ACHN-
CD105+ resensitizes the cell line to gemci-
tabine (A) and reduces the expression of
chemoresistance genes including CDA,
ABCB1, and AICDA (B).
(C–E) Moreover, the overexpression of CDA
(C), C-MYC (D), or NANOG (E) overcomes the
resensitization to gemcitabine induced by
CD105 knockdown. We also treated the
subcutaneous xenograft model (ACHN cells)
with gemcitabine or control via intraperi-
toneal injection in Balb/c-nu nude mice.
(F) The CD105 expression of the tumor
samples was analyzed by flow cytometry,
revealing a higher percentage of CD105+
cells in the gemcitabine-treated tumors
compared with control.
Three independent experiments were un-
dertaken for each assay. **p < 0.01.have been identified, namely CD105-L, CD105-S, and
CD105-v3, with distinct extracellular and intracellular do-
mains (Van Le et al., 2009; Velasco et al., 2008). CD105-v3
was discovered recently in 2015 and its role still remains
unclear. Interestingly, CD105-L and CD105-S appear to
mediate opposing effects on tumor cells. Velasco et al.
(2008) reported that CD105-L promotes cell proliferation
via ALK1/Smad1/Id1, and CD105-S inhibits cells’ growth
potential via the ALK5/Smad2/PAI1 pathway. Also,
CD105-L has been shown to be proangiogenic, while
CD105-S exerts the opposite effect (Perez-Gomez et al.,
2005). Our preliminary analysis showed that the predomi-
nant form of CD105 in the sorted CD105+ cells is CD105-L
(data not shown).We are actively investigating the possible
role of different CD105 isoforms in mediating CSC func-
tions in RCC models.
Our findings suggest that overexpressing CDA, C-MYC,
or NANOG independently can overcome the loss of CSC
functions that resulted from the knockdown or knockout
of CD105 (Figure S5). Importantly, as we overexpressed
CD105-L in the parental cell line from ACHN xenograft,
the gemcitabine resistance and sphere formation ability
were both elevated (Figures S4B–S4D). In contrast to the
increased apoptosis upon shRNA-mediated knockdown,472 Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017the extent of cell senescence was also ameliorated upon
CD105-L overexpression (Figure S4E). In line with our
finding in kidney cancer cell xenografts, shRNA-mediated
knockdown of CD105 can also decrease the self-renewal
capability of CD105+ cells sorted from ccRCC patient
primary tumors (Figure S6). Coincidentally, CD105 thera-
peutic antibody has been on clinical trial in metastatic
castration-resistant prostate cancer (mCRPC) (Karzai
et al., 2015) and other tumors (Rosen et al., 2012). Accord-
ing to the phase ImCRPC trial, TRC105was found to have a
potential effect on the decrease of prostate-specific antigen
velocity, which indicates a potential therapeutic role in
mCRPC patients. Also, the clinical trial of TRC105 in com-
bination with the multi-targeted receptor kinase inhibitor
pazopanib on angiosarcoma has entered phase III (Clinical
Trials, #NCT02979899). Even though the anti-CD105
agent TRC105 was developed as an anti-angiogenic drug,
it is promising that it can also serve as an agent targeting
the tumor-initiating cells in ccRCC.
CDA is a member of the cytidine deaminase protein fam-
ily, which includes AID and APOBEC among others. For a
long time CDA was presumed to only play a role in pyrim-
idine salvaging rather than in other fields, as its siblings do.
In contrast, AID and APOBEC are actively involved in
class-switch recombination, immunoglobulin somatic hy-
permutation, and DNA demethylation (Muramatsu et al.,
2000; Nabel et al., 2012). An abundance of evidence shows
that AID/APOBEC can convert 5-mC (5-methylcytosine) to
thymidine, which would be removed by T-G mismatch-
specific glycosylase (Fritz and Papavasiliou, 2010; Ramiro
and Barreto, 2016). The depleted sites can be subsequently
replaced by an unmethylated cytidine in a base excision
repair process, thereby demethylating the cytosine in the
CpG island. In our study, we speculated that CDA also pos-
sesses a demethylation activity in a similar manner to
AICDA/APOBEC in CD105+ kidney cancer cells. Interest-
ingly, as we knocked out CDA in CD105+-ENG(KO)-CDA
cells, the sphere-formation ability was diminished and
accompanied by downregulation of NANOG and C-MYC
(Figures S7A and S7B). However, as we applied 5-aza-20-de-
oxycytidine in CDA knockout cell lines, the repressed
NANOG and C-MYC protein were both elevated(Fig-
ure S7C), supporting that CDA might also serve as an
important demethylase in CD105+ cells. Nevertheless,
further CpG islandmethylation status analysis on NANOG
and MYC promoters is required to rule out other possible
mechanisms and to validate our finding. Accordingly, a
schematic illustration depicting the possible regulatory cir-
cuit is shown in Figure S7D.
With the ligand binding to TGFb receptor, the activation
of coreceptor endoglin-L can phosphorylate SMADs,
which subsequently serve as transcriptional factors
promoting the transcription of downstream proteins
including CDA, NANOG, and C-MYC. C-MYC (Sussman
et al., 2007; Varlakhanova et al., 2010) and NANOG
(Chiou et al., 2010; Lee et al., 2011; Loh et al., 2006) are
well-known critical transcription factors in both normal
andmalignant stem cells, and drive chemoresistance (Leo-
netti et al., 1999) by promoting either cell apoptosis or
DNA repair (Figure S3E). In terms of the gemcitabine resis-
tance, it is well established that overexpressed CDA can
actively transform gemcitabine into its non-active form,
thereby indirectly inhibiting the production of its active
form 20-difluorodeoxycytidine 50-triphosphate. Also, we
provide evidence hinting that CDA might also play a
role as a demethylase over NANOG and C-MYC promoters
and increase the transcription of these two genes (Mah-
fouz et al., 2013; Zauri et al., 2015). Thus, CDA could
potentially play a role in activating critical stemness regu-
lators such as NANOG and C-MYC.
Taken together, our study showed that CD105 can serve
as a marker to isolate CSCs from human kidney cancer xe-
nografts. Furthermore, CD105 plays a functional role in
maintaining the stem cell phenotype of CSCs. NANOG,
C-MYC, andCDA are three possible downstreammediators
of CD105 that promote self-renewal and chemoresistance.
Also, CDAmight not only play a role as ‘‘shredder’’ of gem-citabine resulting in its resistance, but also may serve as
a demethylase enhancing other genes’ transcription. As
such, CD105 could be a promising therapeutic target to
overcome resistant or recurrent kidney cancer.EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Reagents
The shRNA plasmids for CD105 knockdown were constructed
from pSicoR (Addgene, #11579) with target sequences of shENG1:
GAA AGAGCT TGT TGCGCATand shENG2: AAC AGT CCATTG
TGA CCT TCA. Data presented were from knockdown with
shEGN1, which is consistent with the results from shENG2 (Fig-
ure S3). The ectopic overexpression plasmids of ENG, CDA,
MYC, and NANOG were constructed based on the basic lentiviral
vector.
Regarding antibodies, anti-human OCT-4 (#ab19857), SOX-2
(#ab171380), KLF4 (#ab72543), NANOG (#ab80892), and
C-MYC (#ab32072) were bought from Abcam (MA, USA), anti-hu-
man ACTIN (#AC026) was bought from Abclonal (MA, USA),
anti-human CD105 (#ab169545), CD44 (#ab51037), MUSASHI
(#EP1302), NESTIN (#ab105389), and VIMENTIN (#ab16700)
were bought from Epitomics (CA, USA), anti-human MHC-I
(#GTX105052) and CK7(#GTX109723) were bought from Gene-
tex (CA, USA), and anti-human DLK-1(#AP20959c) and CXCR4
(#AW5434-U080) were bought from Abgent (CA, USA). For flow
cytometry, anti-human CD105 conjugated with PE antibody
(#130-098-906) was bought from Miltenyi (CA, USA).
Ethics Statement
All the protocols in this study were approved by the Ethics Com-
mittee of Tongji Hospital affiliated with Tongji Medical School,
Huazhong University of Science and Technology (HUST). Written
consent was obtained from patients whose tissues were collected
for analysis in this study. All mice in our experiments were kept
in the Specific Pathogen Free (SPF) animal center in TongjiMedical
School, and this study was designed to abide by the principles
stated in the Declaration of Helsinki.
CD105+ Kidney Cancer Cell Subpopulation Isolation
and Maintenance
The kidney cancer cell line ACHN was purchased from ATCC
(Manassas, VA, USA) and maintained at 37C in 5% CO2 in
DMEM-HG (Hyclone, USA) with 10% FBS (Hyclone). A total of
1.0 3 106 ACHN cells were transplanted subcutaneously in the
right axillary fossa of male Balb/c-nu mice. After 1 month of
growth, the tumor was minced with a sterile scalpel and digested
with 0.2% collagenase II (Solarbio, Beijing, China) at 37C for
2 hr with shaking. After washes in PBS, tumor cells were stained
with anti-human CD105-PE antibody (Miltenyi Biotec, CA, USA,
#130-098-906) for 1 hr at 4C and sorted using an MoFlo XDP
cell sorter (Beckman Coulter, USA). The parental cell line and the
sorted CD105+ cancer cell subpopulation were maintained in the
renal CSC expansion medium as described by Bussolati et al.
(2008). The isolation process is summarized in Figure S1A. Expres-
sion of CD105 and the stemness markers as OCT-4, NANOG,Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017 473
SOX-2, Klf-4, and C-MYC were examined every month to confirm
their stemness within 50 passages.
786-O, HK-2, OS-RC-2, CAKI-1, and U937 were purchased from
Shanghai Institute for Biological Sciences of the Chinese Academy
of Sciences. SN12-PM6 cells were a kind gift from Xiaoping Zhang
at UnionHospital affiliated to HuazhongUniversity of Science and
Technology in Wuhan, China.
In Vivo Orthotopic Xenograft Assay with Limiting
Diluted Cells and In Vivo Imaging
In vivo tumorigenicity of cancer cells was determined using
limiting dilution xenografts. CD105+ labeled with EGFP and con-
trol shRNA targeting firefly luciferase, parental cell line labeled
with EGFP and control shRNA, and CD105+_shENG-EGFP cells
labeled with EGFP and shRNA targeting CD105 were cultured in
expansion medium. NOD/SCID mice were injected with serial di-
lutions of cells: 1.0 3 102, 1.0 3 104, and 1.0 3 106, respectively,
with five male NOD/SCID mice per dilution. Cells were trypsi-
nized, rinsed with PBS, and resuspended in 20 mL of Matrigel
diluted with precooled PBS at the ratio of 1:1. Four-week-old
mice were then anesthetized with sterilized 1% pentobarbital so-
dium at the dose of 10 mL/kg via intraperitoneal injection. The
back of each mouse was shaved and the right kidney injected
with 20 mL of cells. After 2 months, 45 mice (15 mice for each
cell line, 5 per dilution for each cell type) were euthanized with
cervical dislocation and sent for in vivo fluorescence imaging
with a home-made whole-body fluorescence imaging system
(Luo et al., 2014; Qian et al., 2016; Yang et al., 2012). The fluores-
cence signal of EGFP was detected through a filter set (excitation
469/35 nm, emission: 510/42 nm). Kidneys from three mice
(two kidneys for each mouse, one with tumor and the other
serving as control) in each cell dilution of each group are shown
in Figures 4 and 6.
In Vivo Gemcitabine-Resistant Assay of CD105+ Cells
in Subcutaneous Xenograft Model
An in vivo subcutaneous xenograft model with ACHN cells was es-
tablished to assess the gemcitabine resistance of CD105+ cells. Ten
male 4-week-old Balb/c-nu mice were randomly grouped into two
groups (5 mice per group). A total of 1 3 106 ACHN cells were re-
suspended in 100 mL of diluted Matrigel (Matrigel and precooled
PBS in a volume ratio of 1:2) and then injected subcutaneously
into the right axillary fossa of each mouse. When the tumor
reached 0.5 cm in diameter, one group of mice was administered
gemcitabine, 0.015 mg/g/day, via intraperitoneal injection on
the first, third, sixth, and ninth day while control mice received
intraperitoneal injection with saline. Ten days after initial treat-
ment, both groups of mice were euthanized and tumors were
resected for flow-cytometric analysis. CD105 expression was
described as above.
Statistical Analysis
Each experiment was performed at least in triplicate unless other-
wise stated. Data are presented as mean ± SD. Significance was
determined by a paired, Student’s t test when there were two
groups or by one-way ANOVA when there were three or more
groups (GraphPad Prism ver6.0). A p value cutoff of 0.05 was474 Stem Cell Reports j Vol. 9 j 464–477 j August 8, 2017used to establish significance. Additional methods and materials
are described in Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, seven figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
07.009.
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